Indications for: DESOXYN
Attention deficit hyperactivity disorder.
Adults and Children:
<6yrs: not established. ≥6yrs: initially 5mg once or twice daily; may increase in increments of 5mg at weekly intervals until response achieved. Usual range: 20–25mg daily in two divided doses.
Advanced arteriosclerosis. Symptomatic cardiovascular disease. Moderate-to-severe hypertension. Hyperthyroidism. Glaucoma. History of drug abuse. Agitation. During or within 14 days of MAOIs. Hypersensitivity to sympathomimetics.
High abuse potential. Misuse may cause sudden death and serious cardiovascular events.
Abuse potential (monitor). If tolerance to anorectic effect develops, discontinue; do not exceed recommended dose. Increased risk of sudden death, stroke, and MI; assess for presence of cardiac disease before initiating. Avoid in known structural cardiac abnormalities, cardiomyopathy, serious arrhythmias, coronary artery disease, and other cardiac problems. Pre-existing psychotic disorder. Bipolar disorder; screen for risk before initiation. Consider discontinuing if new psychotic/manic symptoms occur. Monitor for new or worsening aggressive behavior or hostility. Seizure disorder. Monitor for serotonin syndrome; discontinue if occurs. Evaluate for tics or Tourette's syndrome prior to therapy. Peripheral vasculopathy, including Raynaud's phenomenon; monitor for digital changes. Diabetes. Acute stress reactions. Monitor growth (esp. children), BP, HR. Write ℞ for smallest practical amount. Reevaluate periodically. Pregnancy (Cat.C). Nursing mothers: not recommended.
See Contraindications. Hypertensive crisis with MAOIs (including linezolid, IV methylene blue). Increased risk of serotonin syndrome with serotonergic drugs (eg, SSRIs, SNRIs, TCAs, triptans, fentanyl, lithium, tramadol, tryptophan, busprione, St. John's wort), CYP2D6 inhibitors (eg, paroxetine, fluoxetine, quinidine, ritonavir); consider alternatives; if needed, initiate with lower doses and monitor. Potentiated by urinary alkalinizers (eg, sodium bicarbonate, acetazolamide); avoid. Antagonized by acidifiers (eg, ascorbic acid), phenothiazines. May potentiate TCAs, sympathomimetics; adjust dose or use alternatives. May antagonize guanethidine. May alter insulin requirements in diabetics. Monitor effects with concomitant PPIs. May interfere with urinary steroid test.
Hypertension, tachycardia, palpitation, CNS stimulation, dizziness, dysphoria, insomnia, restlessness, headache, diarrhea, constipation, dry mouth, urticaria, priapism; visual disturbances.